108 related articles for article (PubMed ID: 20111071)
21. The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia.
Geldenhuys WJ; Nair RR; Piktel D; Martin KH; Gibson LF
J Pharmacol Exp Ther; 2019 Jul; 370(1):25-34. PubMed ID: 31010844
[TBL] [Abstract][Full Text] [Related]
22. Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008.
Paz H; Joo EJ; Chou CH; Fei F; Mayo KH; Abdel-Azim H; Ghazarian H; Groffen J; Heisterkamp N
J Exp Clin Cancer Res; 2018 Mar; 37(1):67. PubMed ID: 29580262
[TBL] [Abstract][Full Text] [Related]
23. Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.
Moehler M; Gepfner-Tuma I; Maderer A; Thuss-Patience PC; Ruessel J; Hegewisch-Becker S; Wilke H; Al-Batran SE; Rafiyan MR; Weißinger F; Schmoll HJ; Kullmann F; von Weikersthal LF; Siveke JT; Weusmann J; Kanzler S; Schimanski CC; Otte M; Schollenberger L; Koenig J; Galle PR
BMC Cancer; 2016 Aug; 16(1):699. PubMed ID: 27582078
[TBL] [Abstract][Full Text] [Related]
24. POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.
Sison EA; Magoon D; Li L; Annesley CE; Romagnoli B; Douglas GJ; Tuffin G; Zimmermann J; Brown P
Oncotarget; 2015 Oct; 6(31):30902-18. PubMed ID: 26360610
[TBL] [Abstract][Full Text] [Related]
25. Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia.
George AA; Paz H; Fei F; Kirzner J; Kim YM; Heisterkamp N; Abdel-Azim H
PLoS One; 2015; 10(9):e0137917. PubMed ID: 26360058
[TBL] [Abstract][Full Text] [Related]
26. B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3.
Fei F; Joo EJ; Tarighat SS; Schiffer I; Paz H; Fabbri M; Abdel-Azim H; Groffen J; Heisterkamp N
Oncotarget; 2015 May; 6(13):11378-94. PubMed ID: 25869099
[TBL] [Abstract][Full Text] [Related]
27. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
Sison EA; Magoon D; Li L; Annesley CE; Rau RE; Small D; Brown P
Oncotarget; 2014 Oct; 5(19):8947-58. PubMed ID: 25333254
[TBL] [Abstract][Full Text] [Related]
28. A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo.
Li X; Guo H; Yang Y; Meng J; Liu J; Wang C; Xu H
Sci Rep; 2014 Oct; 4():6610. PubMed ID: 25312253
[TBL] [Abstract][Full Text] [Related]
29. Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R.
Parameswaran R; Lim M; Fei F; Abdel-Azim H; Arutyunyan A; Schiffer I; McLaughlin ME; Gram H; Huet H; Groffen J; Heisterkamp N
Mol Cancer Ther; 2014 Jun; 13(6):1567-77. PubMed ID: 24825858
[TBL] [Abstract][Full Text] [Related]
30. STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.
Dorritie KA; McCubrey JA; Johnson DE
Leukemia; 2014 Feb; 28(2):248-57. PubMed ID: 23797472
[TBL] [Abstract][Full Text] [Related]
31. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
Sison EA; McIntyre E; Magoon D; Brown P
Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844
[TBL] [Abstract][Full Text] [Related]
32. O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia.
Parameswaran R; Lim M; Arutyunyan A; Abdel-Azim H; Hurtz C; Lau K; Müschen M; Yu RK; von Itzstein M; Heisterkamp N; Groffen J
J Exp Med; 2013 Apr; 210(4):805-19. PubMed ID: 23478187
[TBL] [Abstract][Full Text] [Related]
33. Adipose tissue attracts and protects acute lymphoblastic leukemia cells from chemotherapy.
Pramanik R; Sheng X; Ichihara B; Heisterkamp N; Mittelman SD
Leuk Res; 2013 May; 37(5):503-9. PubMed ID: 23332453
[TBL] [Abstract][Full Text] [Related]
34. Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia.
Feldhahn N; Arutyunyan A; Stoddart S; Zhang B; Schmidhuber S; Yi SJ; Kim YM; Groffen J; Heisterkamp N
Oncoimmunology; 2012 Aug; 1(5):618-629. PubMed ID: 22934254
[TBL] [Abstract][Full Text] [Related]
35. Expression of cassini, a murine gamma-satellite sequence conserved in evolution, is regulated in normal and malignant hematopoietic cells.
Arutyunyan A; Stoddart S; Yi SJ; Fei F; Lim M; Groffen P; Feldhahn N; Groffen J; Heisterkamp N
BMC Genomics; 2012 Aug; 13():418. PubMed ID: 22916712
[TBL] [Abstract][Full Text] [Related]
36. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
[TBL] [Abstract][Full Text] [Related]
37. Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.
Agarwal A; Fleischman AG; Petersen CL; MacKenzie R; Luty S; Loriaux M; Druker BJ; Woltjer RL; Deininger MW
Blood; 2012 Sep; 120(13):2658-68. PubMed ID: 22889761
[TBL] [Abstract][Full Text] [Related]
38. Pushing the limits of targeted therapy in chronic myeloid leukaemia.
O'Hare T; Zabriskie MS; Eiring AM; Deininger MW
Nat Rev Cancer; 2012 Jul; 12(8):513-26. PubMed ID: 22825216
[TBL] [Abstract][Full Text] [Related]
39. Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.
Lee L; Fielding AK
Clin Med Insights Oncol; 2012; 6():85-100. PubMed ID: 22346368
[TBL] [Abstract][Full Text] [Related]
40. The bone marrow microenvironment and leukemia: biology and therapeutic targeting.
Sison EA; Brown P
Expert Rev Hematol; 2011 Jun; 4(3):271-83. PubMed ID: 21668393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
